自拟中药方保留灌肠治疗慢性盆腔炎的疗效观察

目的：观察自拟中药方保留灌肠治疗慢性盆腔炎的效果。方法将60例慢性盆腔炎患者随机分为治疗组30例、对照组30例。对照组口服中成药,治疗组在口服中成药的基础上,予自拟中药方保留灌肠。比较2组的临床疗效。结果治疗组30例中,显效18例（60．0％）,有效11例（36．7％）,无效1例（3．3％）,总有效率为96．7％;对照组30例中,显效8例（26．7％）,有效15例（50．0％）,无效7例（23．3％）,总有效率为76.7％。经秩和检验,Z＝－3．873,P＜0．05,说明治疗组临床疗效优于对照组。结论在口服中成药的基础上予自拟中药方保留灌肠治疗慢性盆腔炎具有较好的疗效。     

疏肝通络方治疗糖尿病合并非酒精性脂肪肝临床研究

目的：观察疏肝通络方治疗糖尿病合并非酒精性脂肪肝（ NAFLD ）的临床疗效。方法将120例糖尿病合并NAFLD的患者随机分为治疗组60例、对照组60例,在控制血糖的基础上,对照组采用健康教育、改变生活方式等措施治疗,治疗组在上述基础上加用疏肝通络方口服。结果治疗组60例中,完全缓解5例（8．33％）,显效31例（51．67％）,有效17例（28．33％）,无效7例（11.67％）,总有效率为88．33％;对照组59例中,完全缓解2例（3．39％）,显效12例（20．34％）,有效16例（27．12％）,无效29例（49．15％）,总有效率为50．85％。经Ridit分析,U＝－5．122, P＜0．001,说明治疗组总体疗效优于对照组。2组中医症状积分治疗后较本组治疗前均降低（ P＜0.01）,治疗组较对照组降低更明显（P＜0．05）,说明治疗组优于对照组。2组ALT,AST,TG,TC, LDL-C治疗后均较本组治疗前均降低（P＜0．05,P＜0．01）,治疗组ALT,AST,TG,TC,LDL-C较对照组降低明显（P＜0．05）。 BMI治疗组较治疗前降低（P＜0．01）,对照组治疗前后比较差异无统计学意义（ P＞0．05）。结论疏肝通络方治疗糖尿病合并NAFLD具有较好的疗效。     

Novel Approaches to Improve the Intrinsic Microbiological Safety of Powdered Infant Milk Formula

Human milk is recognised as the best form of nutrition for infants. However; in instances where breast-feeding is not possible, unsuitable or inadequate, infant milk formulae are used as breast milk substitutes. These formulae are designed to provide infants with optimum nutrition for normal growth and development and are available in either powdered or liquid forms. Powdered infant formula is widely used for convenience and economic reasons. However; current manufacturing processes are not capable of producing a sterile powdered infant formula. Due to their immature immune systems and permeable gastro-intestinal tracts, infants can be more susceptible to infection via foodborne pathogenic bacteria than other age-groups. Consumption of powdered infant formula contaminated by pathogenic microbes can be a cause of serious illness. In this review paper, we discuss the current manufacturing practices present in the infant formula industry, the pathogens of greatest concern, Cronobacter and Salmonella and methods of improving the intrinsic safety of powdered infant formula via the addition of antimicrobials such as: bioactive peptides; organic acids; probiotics and prebiotics.     

截断逆挽方对慢加急性肝衰竭大鼠肝细胞进入S期关键蛋白的影响

目的:观察截断逆挽方对慢加急性肝衰竭(ACLF)大鼠肝脏细胞进入S期关键蛋白的影响。方法:将150只Wistar大鼠随机分成3组,正常组(NC)、模型组(MC)及截断逆挽方组(JD)。采用人血清白蛋白联合D-氨基半乳糖和脂多糖急性攻击制作ACLF模型。JD组大鼠在急性攻击24 h后连续灌胃,在第5、10、15天平行取材。运用HE染色法观察大鼠肝脏组织结构,Western blot法检测转录因子E2F1的表达量,RT-PCR检测CyclinA、E和Cdc25 mRNA表达量。结果:与模型组相比,JD组大鼠E2F1的表达量明显增高,并在第10天时差异最为显著(P<0.05),CyclinA、E、Cdc25表达量均有不同程度升高;与正常组相比,JD组大鼠10 d、15 d时CyclinA mRNA表达量差异显著,JD组大鼠在10 d、15 d时Cdc25和CyclinE mRNA表达量均差异显著(P<0.05)。结论:截断逆挽方可以通过调节E2F1介导的细胞再生信号通路上的关键蛋白E2F1、CyclinA、CyclinE、Cdc25的表达,从而促使细胞进入S期,加快DNA复制进程,提高肝细胞的增殖率,发挥治疗ACLF的作用。     

曲安奈德益康唑乳膏联合氯雷他定治疗外耳湿疹的疗效观察

目的：探讨曲安奈德益康唑乳膏联合氯雷他定治疗外耳湿疹的疗效。方法选取2012年3月—2014年3月韶关市第一人民医院收治的外耳湿疹患者108例,随机分为对照组与试验组,各54例。对照组患者给予曲安奈德益康唑乳膏治疗,试验组患者在对照组基础上加用氯雷他定治疗。观察两组患者临床疗效及不良反应发生情况。结果试验组患者总有效率为94.5%,高于对照组的81.5%,差异有统计学意义（ P<0.05）;两组患者不良反应发生率比较,差异无统计学意义（ P>0.05）。结论曲安奈德益康唑乳膏联合氯雷他定治疗外耳湿疹的疗效显著,且不良反应少,安全性高。     

卡铂按AUC计算剂量的计算方法研究进展

血小板减少症是卡铂的剂量限制性毒性。根据肾小球滤过率（GFR）的变量改变影响游离卡铂曲线下面积（AUC）与所给剂量的线性关系,提出了卡铂按AUC给药的计算方法。目前临床上使用Calvert公式计算卡铂剂量,用Cockcroft-Gault公式计算出的肌酐清除率（CrCl）来代替GFR。但是Cockcroft-Gault公式在临床应用中也存在一些局限性。对卡铂的给药剂量计算策略进行综述,找到最佳剂量的计算方法,以供卡铂在临床合理用药和个体化治疗中参考。     

卡泊三醇搽剂联合糠酸莫米松乳膏序惯疗法治疗头皮银屑病临床疗效观察

目的观察卡泊三醇搽剂联合糠酸莫米松乳膏序惯疗法治疗头皮银屑病的疗效及安全性。方法 62例头皮银屑病患者,采用随机对照的方法分为治疗组和对照组,每组31例。治疗组采用卡泊三醇搽剂联合糠酸莫米松乳膏序贯疗法治疗,对照组采用卡泊三醇搽剂治疗。比较两组患者临床疗效、皮损面积评分,并分析其不良反应发生情况。结果治疗2周后,治疗组有效率为45.16%,对照组有效率为32.26%,两组比较差异无统计学意义(χ2=1.09, P>0.05)。治疗4周后,治疗组有效率为67.74%,高于对照组的41.94%,差异有统计学意义(χ2=4.17, P<0.05)。治疗6周后,治疗组有效率87.10%显著高于对照组的64.52%,差异有统计学意义(χ2=4.31, P<0.05)。两组患者治疗前及治疗2周后皮损面积评分比较差异无统计学意义(P>0.05);治疗4、6周后,治疗组患者的皮损面积评分均低于对照组,差异具有统计学意义(P<0.05)。两组患者在治疗过程中均未见严重不良反应,治疗组中2例(6.45%)患者出现局部皮肤轻微烧灼感和疼痛,对照组中2例患者(6.45%)自觉局部轻微灼热不适和疼痛,均未影响治疗,未予处理。结论卡泊三醇搽剂联合糠酸莫米松乳膏序惯疗法治疗头皮银屑病疗效好,安全性高。     

Cytotoxic and Antibacteriial Actiivity of the Mixture of Olive Oil and Lime Cream in Vitro Conditions

The mixture of olive oil and lime cream has been traditionally used to treat external burns in the region of Hatay/Antakya and middle Anatolia. Olive oil and lime cream have been employed by many physicians to treat many ailments in the past. A limited number of studies have shown the antibacterial effect of olive oil and that it does not have any toxic effect on the skin. But we did not find any reported studies on the mixture of olive oil and lime cream. The aim of this paper is to investigate the cytotoxic and antibacterial activity of olive oil and lime cream individually or/and in combination in vitro conditions, by using disk-diffusion method and in cell culture. The main purpose in using this mixture is usually to clear burns without a trace. Agar overlay, MTT (Cytotoxicity assay) and antibacterial susceptibility tests were used to investigate the cytotoxic and antibacterial activity of olive oil and lime cream. We found that lime cream has an antibacterial activity but also cytotoxic on the fibroblasts. On the other hand olive oil has limited or no antibacterial effect and it has little or no cytotoxic on the fibroblasts. When we combined lime cream and olive oil, olive oil reduced its cytotoxic impact. These results suggest that mixture of olive oil and lime cream is not cytotoxic and has antimicrobial activity.     

Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer

Vγ9Vδ2 T cells are promising candidates for cellular tumor immunotherapy. Due to their HLA-independent mode of action, allogeneic Vγ9Vδ2 T cells can be considered for clinical application. To apply allogeneic Vγ9Vδ2 T cells in adoptive immunotherapy, the methodology used to obtain adequate cell numbers with optimal effector function in vitro needs to be optimized, and clinical safety and efficacy also need to be proven. Therefore, we developed a novel formula to improve the expansion of peripheral γδ T cells from healthy donors. Then, we used a humanized mouse model to validate the therapeutic efficacy of expanded γδ T cells in vivo; furthermore, the expanded γδ T cells were adoptively transferred into late-stage liver and lung cancer patients. We found that the expanded cells possessed significantly improved immune effector functions, including proliferation, differentiation, and cancer cell killing, both in vitro and in the humanized mouse model. Furthermore, a phase I clinical trial in 132 late-stage cancer patients with a total of 414 cell infusions unequivocally validated the clinical safety of allogeneic Vγ9Vδ2 T cells. Among these 132 patients, 8 liver cancer patients and 10 lung cancer patients who received ≥5 cell infusions showed greatly prolonged survival, which preliminarily verified the efficacy of allogeneic Vγ9Vδ2 T-cell therapy. Our clinical studies underscore the safety and efficacy of allogeneic Vγ9Vδ2 T-cell immunotherapy, which will inspire further clinical investigations and eventually benefit cancer patients.